Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01183624
NCT01183624CompletedPhase 4

A Multi-Center, Randomized, Double-Blind, Parallel, Placebo Control Study of a Traditional Chinese Medicine Topical Analgesic Patch in the Treatment of Osteoarthritis of the Knee

Johnson & Johnson Consumer and Personal Products Worldwide12 sites in 1 country626 target enrollmentStarted: July 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
626
Locations
12
Primary Endpoint
Pain Score
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

An evaluation of the safety and efficacy of an herbal patch in treating osteoarthritis pain of the right or left knee.

Detailed Description

This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study of herbal patch in subjects with OA knee pain. The overall objective of this study is to evaluate the efficacy and safety of the patch in relieving OA knee pain.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
40 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female between 40 and 70 years of age
  • •Medically cleared to participate by a site affiliated physician following a physical
  • •History of, or current diagnosis of, OA of the knee
  • •Evidence of idiopathic OA of at least one knee
  • •Subject Assessment of OA pain in target knee 40 - 75 mm (on the 100 mm VAS inclusive) in the index knee, on the WOMAC Pain composite subscale at Visit 1
  • •Subject Assessment of OA pain in non-index knee (if applicable) is ≤ 20mm
  • •Subject Global Assessment of OA Condition (5 pt categorical scale, 1 = very good to 5 = very poor) of grade 3-5 (i.e. fair, poor or very poor)
  • •Evidence of idiopathic OA of at least one knee as defined by the American College of Rheumatology Classification (ACR) of OA of the Knee

Exclusion Criteria

  • •Grade 1 or Grade 4 severity of the index knee based on the Kellgren and Lawrence radiographic criteria
  • •Pain greater than 20 mm on the VAS in the non-index knee (either at rest or with movement)
  • •Prior injection or arthroscopy of study knee within 3 months
  • •Crystalline-induced synovitis (e.g. gout, pseudo gout, nonsteroid arthritis, hydroxyapatite deposit), acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, fibromyalgia, systemic lupus, erythematosus collagen vascular disease or other types of inflammatory arthritis in the index knee
  • •Pain in either knee is of neurological origin
  • •An injury or surgery to the same body region within the prior 6 months or a lifetime history of 3 or more injuries/surgeries to the injured body region
  • •Signs of clinically important active inflammation of the study knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits
  • •Other criteria that - in the opinion of the investigator - may jeopardize the safety of the subject or the study results.

Outcomes

Primary Outcomes

Pain Score

Time Frame: Day 7

The WOMAC (Western Ontario and McMaster Universities Index of Osteoarthritis) Pain Subscale Score

Secondary Outcomes

  • Subject Assessment(Day 14)
  • Investigator Assessment(Day 14)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (12)

Loading locations...

Similar Trials

Unknown
Phase 1
Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of ArthritisTreatment of Arthritis
NCT03506919Shifa Ul Mulk Memorial Hospital200
Withdrawn
Phase 2
The Use of Cannabinoid Patch for Knee OsteoarthritisCBDOsteoarthritisKnee Osteoarthritis
NCT04412837Northwell Health
Unknown
Phase 4
Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE)Osteoarthritis, Knee
NCT02323451Shanghai Qisheng Biological Preparation Co., Ltd.270
Completed
Not Applicable
Osteopathic Medicine in Fibromyalgia SyndromeFibromyalgia Syndrome
NCT02343237Assistance Publique - Hôpitaux de Paris101
Completed
Not Applicable
Clinical Trial of Low-dose Radiation Therapy in Patients With Knee Osteoarthritis (LoRD-KNeA Trial)Knee Osteoarthritis
NCT05562271Seoul National University Hospital114